Citeline
Candel Therapeutics received the 2025 SCRIP Award in the category Best Oncology R&D Advance
Media
Check out our latest corporate updates, features in the media, and scientific publications and presentations.
Company Videos
Media
Parade
‘My Memory Started to Fade As He Drove Me to the Hospital,’ Says Woman Who Swore She ‘Just’ had COVID
2026
Pharma Now
CAN-2409 By Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Status For Prostate Cancer
2025
Urology Times
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
2025
Cancer Network
Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer
2025
Biopharma Boardroom
Candel Therapeutics Secures FDA RMAT Designation for CAN-2409 in Localized Prostate Cancer
2025
The Clinical Vanguard
Candel Therapeutics Gets FDA Nod for Prostate Cancer Treatment
2025
Dow Jones
Candel Shares Rise After FDA Regenerative Medicine Advanced Therapy Designation
2025
Drug Discovery World
Gene delivery evolution: Advancing novel cancer immunotherapies
2025
Pharma Features
Enhancing Analytical Method Development: Supporting Cohesive CMC Integration Across Drug Lifecycle Management with Seshu Tyagarajan, Candel Therapeutics
2025
Rare Cancer News
CAN-2409 combo therapy shows survival benefits in brain cancer
2025
Biotech TV
Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech
2025
OncLive
CAN-2049 Displays Potential OS Benefit in Advanced NSCLC After Inadequate Response to Checkpoint Inhibitors
2025
Fierce Biotech
Candel’s lung cancer survival data light path toward pivotal trial in subpopulation
2025
First Word Pharma
Candel’s immunotherapy streak continues with lung cancer win
2025
Rare Cancer News
Immunotherapy shows promise as treatment for pancreatic cancer
2025
Cancer Network
CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC
2025
Onco Daily
Paul Peter Tak: Positive final survival data from CAN-2409 in borderline resectable pancreatic cancer
2025
The Pharma Letter
Candel reports extended survival in Phase II CAN-2409 trial
2025
Endpoints
Candel’s viral therapy shows promising survival in small pancreatic cancer study
2025
Pharma Voice
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
2025
BioTuesdays
Candel is enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies
2024
Targeted Oncology
CAN-2409/Vancyclovir Leads to Positive Tolerability, Immune Response in NSCLC
2024
Progress, Potential, and Possibilities Podcast
Dr. Paul Peter Tak, MD, PhD – Developing Novel Viral Immunotherapies To Improve Cancer Outcomes with Ira Pastor of Progress, Potential, and Possibilities Podcast
2024
Urology Times
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
2024
Endpoints
Candel’s shares soar on Phase 3 prostate cancer data despite unclear prospects
2024
Fierce Biotech
Candel burns bright as phase 3 prostate cancer win sends stock up 200%
2024
Clinical Trials Arena
Candel Therapeutics stock up 172% after Phase III prostate cancer success
2024
The Pharma Letter
Candel’s CAN-2409 hits goal in Phase III prostate cancer trial
2024
BioTuesdays
Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer
2024
Investor’s Business Daily
Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug
2024
Clinical Leader
What’s Needed To Transform Clinical Trials In Early-Stage Prostate Cancer
2024
MedCity News
Prostate Cancer Management – We Need Better Options for Early-Stage Disease
2024
DocWire News
Paul Peter Tak, CEO of Candel Therapeutics, Discusses the Treatment of Glioblastoma
2025
BioTuesdays
Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies
2024
Target Oncology
CAN-2409/Vancyclovir Leads to Positive Tolerability, Immune Response in NSCLC
2024
Progress, Potential, and Possibilities
Dr. Paul-Peter Tak, MD, PhD – Developing Novel Viral Immunotherapies To Improve Cancer Outcomes
2024
Posters & Presentations
American Urological Association Annual Meeting 2026
Extended follow-up shows accumulating benefit for patients treated with aglatimagenebesadenovec (CAN-2409) + prodrug in combination with standard-of-care external beam radiation (EBRT) in men with localized prostate cancer: update from arandomized placebo-controlled phase 3 clinical trial
Oral Presentation | Mark Garzotto, MD
2026
Society for Immunotherapy of Cancer (SITC) 2025
Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
Poster Presentation
2025
Society for Immunotherapy of Cancer (SITC) 2025
Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering
Poster Presentation
2025
American Society for Radiation Oncology (ASTRO) Annual Meeting 2025
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer
Oral Presentation | Glen Gejerman, MD, MBA
2025
American Society of Clinical Oncology (ASCO) Annual Meeting 2025
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer
Oral Presentation | Theodore L. DeWeese, MD
2025
Society for Immunotherapy of Cancer (SITC) 2024
Therapeutic potential of CAN-3110 in RAS-RAF pathway altered melanoma
Poster Presentation | Anne Diers, PhD
2024
16th Annual International Oncolytic Virotherapy Conference
Oncolytic immunactivation clinical trial in rHGG: Preliminary safety and feasibility from longitudinal injections
Oral Presentation | E. Antonio Chiocca, MD, PhD
2024
16th Annual International Oncolytic Virotherapy Conference
A first-in-class multimodel immunotherapy for enhanced immune activation in the tumor microenvironment as a novel strategy for solid tumors
Poster Presentation | Qiuchen Guo, PhD
2024
American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Overall survival after treatment with CAN-2409 plus valcyclovir in combination with continued ICI in patients with Stage III/IV NSCLC with inadequate response to ICI
Poster Presentation | Charu Aggarwal, MD, MPH
2024
American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Longitudinal sterotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM);
Poster Presentation | David Reardon, MD
2024
American Association for Cancer Research (AACR) Annual Meeting 2024
A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors
Poster Presentation | Francesca Barone, MD, PhD
2024
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Neoadjuvant CAN-2409 + Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC)
Poster Presentation | W. Garrett Nichols, MD, MS
2023
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Development of enLIGHTEN Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
Poster Presentation | Francesca Barone, MD, PhD
2023
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
A novel viral immunotherapeutic targeting the CD47/SIRPa axis demonstrates potent anti-tumor effects
Poster Presentation | Anne R. Diers, PhD
2023
American Society of Clinical Oncology (ASCO) Annual Meeting 2023
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC
Trials-In-Progress Poster | Charu Aggarwal, MD, MPH
2023
26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Safety and survival outcomes in recurrent high-grade glioma patient treated with CAN-3110, a first-in-class ICP34.5 expressing oncolytic HSV1
Oral Presentation | Francesca Barone, MD, PhD
2023
37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Oral Presentation | Patrick Y. Wen, MD
2022
37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice
Poster Presentation | Anne R. Diers, PhD
2022
American Society of Clinical Oncology (ASCO) Annual Meeting 2022
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
Poster Presentation | Charu Aggarwal, MD, MPH
2022
36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
Oral Presentation | Patrick Y. Wen, MD
2021
36th Annual Meeting of the Society for Neuro-Oncology (SNO)
Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
Poster Presentation | Francesca Barone, MD, PhD
2021
28th Annual Prostate Cancer Foundation’s Scientific Retreat
Patient experience with intraprostatic injection of CAN-2409 or placebo followed by valacyclovir in a phase 3 clinical trial for localized prostate cancer in combination with standard of care radiation therapy with or without androgen suppression
Poster Presentation | Laura K. Aguilar, MD
2021
Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit
Oncolytic Virus Immunotherapy, Tipping the balance in favor of the immune system to fight cancer
Oral Presentation | Paul Peter Tak, MD, PhD, FMedSci
2021
Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)
Oral Presentation | Scott Eggener, MD
2021
American Society of Clinical Oncology (ASCO) Annual Meeting 2021
First in human clinical trial with CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma
Oral Presentation | E. Antonio Chiocca, MD PhD
2021
Publications
Patrick Y. Wen, et al. Society for Neuro-Oncology
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma
2025
Pedro R. Lowenstein. Science Translational Medicine
Now you see me; now you don’t
2025
Ling AL et al. Science Translational Medicine
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
2025
Ling AL et al. Nature
Perturbing Clinical trials links oncolytic immunoactivation to survival in glioblastoma.
2023
Koch MS et al. Molecular Therapy Oncolytics
Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.
2022
Koch MS et al. Journal for ImmunoTherapy of Cancer
J Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
2022
Rahman et al. The Lancet Oncology
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
2021
Predina et al. Molecular Therapy
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity
2020
Kieran et al. Neuro-Oncology
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
2019
Aggarwal et al. Molecular Therapy
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion
2018
Speranza et al. Neuro-Oncology
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
2018
Wheeler et al. Neuro-Oncology
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
2016
Aguilar et al. Cancer Immunology, Immunotherapy
Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
2015
